Alectinib is a highly selective, central nervous system (CNS)-active ALK inhibitor, which is recommended as a first-line treatment option for patients with advanced ALK-positive NSCLC in a number of treatment guidelines.1, 2, 3. This evidence concerns the gene ALK and non-small cell lung carcinoma.